Thick and thin

Cardiovascular company Regado Biosciences Inc. has lined up a management team pulled largely from pharma and secured a $40 million D round to get it through a Phase IIb trial of its lead candidate.

The company's REG1 Anticoagulation System is in Phase IIb testing as an anticoagulant therapy in acute coronary syndrome (ACS) patients undergoing cardiac catheterization. Top-line data are expected by YE10...